KR20150092358A - 활성 및 비활성 단백질 ｃ에 대한 모노클로날 항체 - Google Patents

활성 및 비활성 단백질 ｃ에 대한 모노클로날 항체 Download PDF

Info

Publication number
KR20150092358A
KR20150092358A KR1020157020430A KR20157020430A KR20150092358A KR 20150092358 A KR20150092358 A KR 20150092358A KR 1020157020430 A KR1020157020430 A KR 1020157020430A KR 20157020430 A KR20157020430 A KR 20157020430A KR 20150092358 A KR20150092358 A KR 20150092358A
Authority
KR
South Korea
Prior art keywords
antibody
apc
protein
monoclonal antibody
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157020430A
Other languages
English (en)
Korean (ko)
Inventor
쥔 쉬
찰스 에스몬
Original Assignee
오클라호마 메디컬 리써치 화운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오클라호마 메디컬 리써치 화운데이션 filed Critical 오클라호마 메디컬 리써치 화운데이션
Publication of KR20150092358A publication Critical patent/KR20150092358A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
KR1020157020430A 2007-10-26 2008-10-24 활성 및 비활성 단백질 ｃ에 대한 모노클로날 항체 Ceased KR20150092358A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98309207P 2007-10-26 2007-10-26
US60/983,092 2007-10-26
PCT/US2008/081110 WO2009055669A2 (en) 2007-10-26 2008-10-24 Monoclonal antibodies against activated and unactivated protein c

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020107011548A Division KR101856210B1 (ko) 2007-10-26 2008-10-24 활성 및 비활성 단백질 ｃ에 대한 모노클로날 항체

Publications (1)

Publication Number Publication Date
KR20150092358A true KR20150092358A (ko) 2015-08-12

Family

ID=40289112

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157020430A Ceased KR20150092358A (ko) 2007-10-26 2008-10-24 활성 및 비활성 단백질 ｃ에 대한 모노클로날 항체
KR1020107011548A Active KR101856210B1 (ko) 2007-10-26 2008-10-24 활성 및 비활성 단백질 ｃ에 대한 모노클로날 항체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020107011548A Active KR101856210B1 (ko) 2007-10-26 2008-10-24 활성 및 비활성 단백질 ｃ에 대한 모노클로날 항체

Country Status (13)

Country Link
US (3) US8153766B2 (https=)
EP (1) EP2205638B1 (https=)
JP (3) JP2011500843A (https=)
KR (2) KR20150092358A (https=)
CN (3) CN105153308A (https=)
AU (1) AU2008316661B2 (https=)
BR (1) BRPI0818865A2 (https=)
CA (1) CA2703738C (https=)
IL (2) IL205284A (https=)
MX (1) MX2010004615A (https=)
RU (2) RU2539729C2 (https=)
WO (1) WO2009055669A2 (https=)
ZA (1) ZA201105704B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201700360VA (en) * 2012-03-16 2017-03-30 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
CN104812402A (zh) * 2012-11-29 2015-07-29 拜尔健康护理有限责任公司 针对活化蛋白C (aPC)的单克隆抗体
HK1215174A1 (zh) * 2012-11-29 2016-08-19 Bayer Healthcare Llc 針對活化蛋白c的人源化單克隆抗體及其用途
WO2015041310A1 (ja) 2013-09-20 2015-03-26 中外製薬株式会社 抗プロテインｃ抗体による出血性疾患の治療
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
WO2015179435A1 (en) * 2014-05-19 2015-11-26 Bayer Healthcare Llc Optimized humanized monoclonal antibodies against activated protein c and uses thereof
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
NZ754713A (en) 2016-12-21 2025-11-28 Teneobio Inc Anti-bcma heavy chain-only antibodies
IL271194B2 (en) 2017-06-20 2024-10-01 Teneobio Inc Anti-bcma heavy chain-only antibodies
WO2019009407A1 (ja) * 2017-07-07 2019-01-10 第一三共株式会社 抗プロテインｃ抗体
WO2019016392A1 (en) 2017-07-20 2019-01-24 Nbe-Therapeutics Ag HUMAN ANTIBODIES BINDING TO ROR2
EP3971572A1 (en) * 2017-09-13 2022-03-23 B.R.A.H.M.S GmbH Proadrenomedullin as a marker for abnormal platelet levels
WO2020051277A1 (en) * 2018-09-06 2020-03-12 Board Of Regents, The University Of Texas System Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein c receptor (epcr)
JP7248788B2 (ja) * 2018-10-18 2023-03-29 オクラホマ メディカル リサーチ ファウンデーション 疾患活動性を特徴付ける全身性エリテマトーデス（ｓｌｅ）疾患活動性免疫指標のバイオマーカー
CN109897108B (zh) * 2019-03-11 2021-04-02 上海恒赛生物科技有限公司 抗人内皮蛋白c受体的羊驼单域抗体及应用
CN115611986B (zh) * 2021-07-13 2025-08-12 上海莱士血液制品股份有限公司 针对人活化蛋白c的单克隆抗体及其制备和应用
CA3245346A1 (en) * 2022-03-04 2023-09-07 Coagulant Therapeutics Corporation Camelid antibodies directed against activated protein C and their uses
CN118370814A (zh) * 2023-01-20 2024-07-23 上海莱士血液制品股份有限公司 一种抗aPC单克隆抗体的制剂及其应用
KR20250000042A (ko) 2023-06-23 2025-01-02 충남대학교산학협력단 절단 반응성 펩타이드를 발현하는 키메라 t 세포 및 이를 포함하는 감염 질환 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247453B1 (en) * 1988-12-30 2007-07-24 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein C
US5202253A (en) * 1988-12-30 1993-04-13 Oklahoma Medical Research Foundation Monoclonal antibody specific for protein C and antibody purification method
US5279956A (en) * 1991-06-24 1994-01-18 The Scripps Research Institute Activated protein C polypeptides and anti-peptide antibodies, diagnostic methods and systems for inhibiting activated protein C
US5695993A (en) 1994-08-12 1997-12-09 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
ATE464374T1 (de) * 2000-10-02 2010-04-15 Oklahoma Med Res Found Assay zum schnellen nachweis vom humanen aktivierten protein c und hochspezifischer monoklonaler antikörper dagegen
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same

Also Published As

Publication number Publication date
IL205284A0 (en) 2010-12-30
AU2008316661A1 (en) 2009-04-30
JP2013049694A (ja) 2013-03-14
CA2703738A1 (en) 2009-04-30
KR101856210B1 (ko) 2018-05-09
JP6117741B2 (ja) 2017-04-19
ZA201105704B (en) 2014-05-28
JP2011500843A (ja) 2011-01-06
RU2012150953A (ru) 2014-06-10
US9127072B2 (en) 2015-09-08
US20120164150A1 (en) 2012-06-28
CN103232541A (zh) 2013-08-07
IL220622A0 (en) 2012-08-30
CN105153308A (zh) 2015-12-16
AU2008316661B2 (en) 2013-05-23
IL205284A (en) 2014-06-30
WO2009055669A2 (en) 2009-04-30
RU2539729C2 (ru) 2015-01-27
US8153766B2 (en) 2012-04-10
CN101918453A (zh) 2010-12-15
CA2703738C (en) 2018-02-27
WO2009055669A3 (en) 2009-09-03
EP2205638A2 (en) 2010-07-14
KR20100116166A (ko) 2010-10-29
EP2205638B1 (en) 2017-03-01
MX2010004615A (es) 2010-07-06
US20090110683A1 (en) 2009-04-30
RU2010121148A (ru) 2011-12-10
BRPI0818865A2 (pt) 2015-05-05
US20150344588A1 (en) 2015-12-03
JP2014237651A (ja) 2014-12-18

Similar Documents

Publication Publication Date Title
KR101856210B1 (ko) 활성 및 비활성 단백질 ｃ에 대한 모노클로날 항체
JP6669800B2 (ja) Ｍａｓｐ−２依存性の補体活性化を阻害するための組成物
US20220233705A1 (en) Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
CN106163556B (zh) 基质金属蛋白酶底物和其它可切割部分及其使用方法
AU2022241636B2 (en) Method of treating atherosclerosis
US12357691B2 (en) Antibodies specifically binding to CD147 and uses thereof
WO2015158851A1 (en) Antibodies for the prevention or the treatment of bleeding episodes
US9463217B1 (en) Methods and pharmaceutical compositions for treatment of retinal occlusion
AU2016203760B2 (en) Monoclonal antibodies against activated and unactivated protein c
AU2015200348B2 (en) Monoclonal antibodies against activated and unactivated protein c
AU2013202464B2 (en) Monoclonal antibodies against activated and unactivated protein c
HK1187631A (en) Monoclonal antibodies against activated and unactivated protein c
EP4085252A1 (en) Methods for detection of pathogenic antiphospholipid antibodies and for identification of inhibitors

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20150727

Application number text: 1020107011548

Filing date: 20100526

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150825

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151118

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160525

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160812

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160525

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20151118

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I